Sagimet Biosciences (SGMT) Return on Capital Employed (2023 - 2026)

Sagimet Biosciences' Return on Capital Employed history runs 4 years deep, the most recent figure standing at 45.62% for Q1 2026.

• In Q1 2026, Return on Capital Employed changed N/A year-over-year to 45.62%; the TTM figure through Mar 2026 stood at 45.62% (changed N/A YoY), while the FY2025 annual figure was 42.69%, up 121.0% from the prior year.
• Return on Capital Employed was 45.62% for Q1 2026 at Sagimet Biosciences, up from 48.48% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 32.64% in Q4 2023 to a low of 51.97% in Q3 2025.
• Historically, Return on Capital Employed has averaged 44.57% across 4 years, with a median of 48.48% in 2025.
• The sharpest annual moves came in 2024 and 2025: Return on Capital Employed sank 75 bps in 2024, then slumped 1509 bps in 2025.
• A 4-year view of Return on Capital Employed shows it stood at 32.64% in 2023, then decreased by 2 bps to 33.39% in 2024, then slumped by 45 bps to 48.48% in 2025, then climbed by 6 bps to 45.62% in 2026.
• The last three Return on Capital Employed figures came in at 45.62% (Q1 2026), 48.48% (Q4 2025), and 51.97% (Q3 2025), per Business Quant data.